Release
2024/10/28
OSAKA, Japan, October 28, 2024 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that it has made the following revisions to its consolidated earnings forecasts for the full year ending on March 31, 2025. The prior earnings forecasts were released on May 13, 2024.
1. Revisions to consolidated earnings forecasts
Revisions to consolidated forecasts for the fiscal year ending March 31, 2025 (April 1, 2024 – March 31, 2025)
(Millions of yen)
|
Net sales |
Operating income |
Profit before tax |
Profit attributable to owners of parent |
share (yen)* |
Previous forecast (A) |
455,000 |
160,000 |
200,000 |
163,000 |
191.66 |
Revised forecast (B) |
460,000 |
165,000 |
206,000 |
171,000 |
201.03 |
Change (B-A) |
＋5,000 |
＋5,000 |
＋6,000 |
＋8,000 |
－ |
Change (%) |
＋1.1 |
＋3.1 |
＋3.0 |
＋4.9 |
－ |
[Reference] |
|||||
Results for the fiscal year ended March 31, 2024 |
435,081 |
153,310 |
198,283 |
162,030 |
186.17 |
Y on Y change (%) |
＋5.7 |
＋7.6 |
＋3.9 |
＋5.5 |
－ |
* SHIONOGI conducted a 3-for-1 stock split of shares of common stock, effective October 1, 2024. Basic earnings per share was calculated under the assumption that the stock split had been conducted at the beginning of the year ended March 31, 2024.
1. Reasons for revisions to consolidated earnings forecasts
During the second quarter consolidated cumulative period, we exceeded our performance forecasts in terms of revenue and all profit items. Overseas business achieved steady sales, particularly driven by cefiderocol. Regarding the HIV business, we saw continued growth in royalty income and dividends from ViiV Healthcare, with sales growth centered on Cabenuva, Apretude, and Dovato. Regarding the domestic business, the revenue from infectious disease drugs fell short of expectations due to a significant decrease in the number of influenza and COVID-19 cases compared to the same period last year. However, the influenza treatment Xofluza and the COVID-19 treatment Xocova have each attained the target market share in their respective treatment markets, and their shares continue to increase. Therefore, it is expected that they will contribute steadily to performance. Additionally, from the third quarter onwards, we will pursue expanded sales activities in the QOL disease area, less affected by epidemics, as a new revenue base. In particular, the insomnia treatment, Quviviq® tablets (generic name: daridorexant, hereinafter referred to as Quviviq), for which we signed a sales partnership agreement with Nxera Pharma Japan Co., Ltd. is expected to contribute meaningfully. 1
Reflecting the favorable trends in the overseas business and HIV business, as well as the expected contribution of Quviviq, we revised our forecast upwards.
Note: The forecasts shown in the material herein are based on currently available information as of October 28, 2024. Actual performance may differ materially from these forecasted figures due to various factors in the future.
Reference
1. Press release on Ocotober 1, 2024
Regarding the Conclusion of Sales Partnership Agreement with Nxera Pharma Japan for the Insomnia Treatment “QUVIVIQ®”
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html